{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:49:55Z","timestamp":1791859795731,"version":"4.3.4"},"reference-count":21,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2025.2851","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:14:01Z","timestamp":1744877641000},"page":"1-13","source":"Crossref","is-referenced-by-count":1,"title":["Peripheral biomarkers predict survival in patients with glioblastoma treated with temozolomide"],"prefix":"10.3892","volume":"22","author":[{"given":"Shuodan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Mcmillan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mcguinness","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Trudeau","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka-Wai","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Uhlmann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"key20250513105900_b1-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key20250513105900_b2-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1053\/j.seminoncol.2003.11.031","article-title":"Factors influencing survival in high-grade gliomas","volume":"30 (6 Suppl 19)","author":"Buckner","year":"2003","journal-title":"Semin Oncol"},{"key":"key20250513105900_b3-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3171\/JNS\/2008\/108\/4\/0642","article-title":"Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma","volume":"108","author":"Barnholtz-Sloan","year":"2008","journal-title":"J Neurosurg"},{"key":"key20250513105900_b4-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1002\/cncr.27570","article-title":"Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older","volume":"118","author":"Scott","year":"2012","journal-title":"Cancer"},{"key":"key20250513105900_b5-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"vii17","DOI":"10.1093\/neuonc\/noy158","article-title":"Updates in prognostic markers for gliomas","volume":"20 (Suppl 7)","author":"Aquilanti","year":"2018","journal-title":"Neuro Oncol"},{"key":"key20250513105900_b6-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"key20250513105900_b7-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis"},{"key":"key20250513105900_b8-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","article-title":"Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents","volume":"343","author":"Esteller","year":"2000","journal-title":"N Engl J Med"},{"issue":"e55665","key":"key20250513105900_b9-MCO-22-6-02851","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055665","article-title":"Survival and death strategies in glioma cells: Autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage","volume":"8","author":"Knizhnik","year":"2013","journal-title":"PLoS One"},{"key":"key20250513105900_b10-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1215\/15228517-2006-024","article-title":"The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas","volume":"9","author":"Gerber","year":"2007","journal-title":"Neuro Oncol"},{"key":"key20250513105900_b11-MCO-22-6-02851","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1182\/blood.V88.5.1649.1649","article-title":"Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU","volume":"88","author":"Gerson","year":"1996","journal-title":"Blood"},{"key":"key20250513105900_b12-MCO-22-6-02851","first-page":"44","article-title":"Low leukocyte MGMT accompanies temzolomide-induced myelotoxicity in brain tumor patients","volume":"1","author":"Stokes","year":"2012","journal-title":"J Can Res Updates"},{"key":"key20250513105900_b13-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1093\/annonc\/mdu444","article-title":"Association between treatment toxicity and outcomes in oncology clinical trials","volume":"25","author":"Abola","year":"2014","journal-title":"Ann Oncol"},{"key":"key20250513105900_b14-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","article-title":"Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials","volume":"6","author":"Di Maio","year":"2005","journal-title":"Lancet Oncol"},{"key":"key20250513105900_b15-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3171\/2016.7.JNS16609","article-title":"Bone marrow response as a potential biomarker of outcomes in glioblastoma patients","volume":"127","author":"Vaios","year":"2017","journal-title":"J Neurosurg"},{"key":"key20250513105900_b16-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10143-017-0903-3","article-title":"Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients","volume":"41","author":"Saito","year":"2018","journal-title":"Neurosurg Rev"},{"issue":"80","key":"key20250513105900_b17-MCO-22-6-02851","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2020.2150","article-title":"Leukopenia is a biomarker for effective temozolomide dosing and predicts overall survival of patients with glioblastoma","volume":"13","author":"Ho","year":"2020","journal-title":"Mol Clin Oncol"},{"key":"key20250513105900_b18-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/neuonc\/noac070","article-title":"Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma","volume":"24","author":"Le Rhun","year":"2022","journal-title":"Neuro Oncol"},{"key":"key20250513105900_b19-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nec.2009.08.012","article-title":"The role of tregs in glioma-mediated immunosuppression: Potential target for intervention","volume":"21","author":"Humphries","year":"2010","journal-title":"Neurosurg Clin N Am"},{"key":"key20250513105900_b20-MCO-22-6-02851","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00432-012-1243-x","article-title":"Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: A novel prognostic factor for survival","volume":"138","author":"Williams","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"issue":"569","key":"key20250513105900_b21-MCO-22-6-02851","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040569","article-title":"The role of platelets in cancer pathophysiology: Focus on malignant glioma","volume":"11","author":"Marx","year":"2019","journal-title":"Cancers (Basel)"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:59:07Z","timestamp":1747123147000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2025.2851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":21,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,17]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2025.2851","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]}}}